- A patient is prescribed an MAO inhibitor for depression. The clinician explains that dietary tyramine restrictions are crucial because the medication inhibits MAO-A in the gut wall and liver. The inhibition of MAO-A is clinically central to both the hypertensive risk with tyramine and the antidepressant effect because MAO-A preferentially metabolizes which two key monoamines?
Answer: Serotonin and norepinephrine
The two isoforms of monoamine oxidase have different substrate specificities. MAO-A is the primary metabolizer of serotonin and norepinephrine, as well as dopamine and tyramine. Its inhibition is responsible for the main antidepressant effects of non-selective MAOIs and for the risk of serotonin syndrome and hypertensive crisis. MAO-B preferentially metabolizes dopamine and phenethylamine. While dopamine is a substrate for both, the combination of serotonin and norepinephrine is unique to MAO-A's primary responsibilities, making its inhibition key to the major therapeutic effects and risks of these drugs.
- An elderly patient on long-term warfarin therapy is started on sertraline for depression. The physician should counsel the patient about an increased risk of bleeding. This increased risk is primarily due to sertraline's effect on which of the following?
Answer: Depletion of serotonin from platelets, which impairs their aggregation function.
When you encounter drug interactions involving bleeding risk, think about the multiple mechanisms by which medications can affect hemostasis: platelet function, coagulation factors, or drug metabolism.
Sertraline, an SSRI antidepressant, increases bleeding risk primarily through its effect on platelet serotonin. Platelets normally store serotonin in dense granules and release it during activation to promote aggregation and clot formation. SSRIs block the serotonin reuptake transporter (SERT) on platelet membranes, preventing platelets from taking up and storing serotonin from plasma. This serotonin depletion impairs platelet aggregation function, creating a bleeding tendency that becomes especially concerning when combined with anticoagulants like warfarin. This makes option A correct.
Option B is incorrect because sertraline doesn't cause bone marrow toxicity or thrombocytopenia - the platelet count remains normal, but platelet function is impaired. Option C represents a common misconception about this interaction. While sertraline does have some CYP450 inhibitory effects, it primarily inhibits CYP2D6, not CYP2C9 (warfarin's main metabolizing enzyme). The bleeding risk occurs even without significant changes in warfarin levels. Option D is also wrong - sertraline doesn't significantly displace warfarin from albumin binding sites.
Remember this pattern: SSRIs increase bleeding risk through platelet dysfunction, not through traditional pharmacokinetic drug interactions. This mechanism explains why bleeding risk occurs with SSRIs even in patients not taking anticoagulants, though the combination creates additive risk.
- A 65-year-old patient is prescribed amitriptyline for chronic insomnia and postherpetic neuralgia. The patient complains of significant dry mouth, constipation, and blurred vision. These side effects are mediated by the drug's antagonist activity at which receptor type?
Answer: Muscarinic M1 receptors
The constellation of dry mouth (xerostomia), constipation, blurred vision (cycloplegia), and urinary retention are classic anticholinergic side effects. These are caused by the blockade of muscarinic acetylcholine receptors, particularly the M1 subtype. Tricyclic antidepressants like amitriptyline are potent muscarinic receptor antagonists. Antagonism of histamine H1 receptors (A) primarily causes sedation and weight gain. Antagonism of alpha-1 adrenergic receptors (C) causes orthostatic hypotension and dizziness. Antagonism of 5-HT2C receptors (D) is associated with anxiolysis and appetite stimulation, but not the classic anticholinergic triad.
- A patient with depression and severe hepatic impairment requires antidepressant therapy. Which of the following drugs is converted to a long-acting, pharmacologically active metabolite that would be expected to accumulate and prolong the risk of adverse effects in this patient?
Answer: Fluoxetine
Fluoxetine is metabolized in the liver to norfluoxetine, an active metabolite that is also a potent SSRI. Norfluoxetine has an extremely long half-life (4 to 16 days). In a patient with hepatic impairment, the clearance of both fluoxetine and norfluoxetine is significantly reduced. This leads to accumulation of the active compounds, prolonging the drug's effects and increasing the risk of adverse events like serotonin syndrome. The other agents listed do not have metabolites with such a long half-life and significant clinical activity, making fluoxetine a particularly risky choice in this population.
- A 24-year-old patient is brought to the emergency department after ingesting an entire bottle of amitriptyline. An ECG reveals a QRS duration of 140 ms and sinus tachycardia. The primary mechanism responsible for this specific ECG finding is the blockade of which of the following channels in the myocardium?
Answer: Fast voltage-gated sodium channels
Tricyclic antidepressants (TCAs) like amitriptyline are potent inhibitors of fast voltage-gated sodium channels (Nav1.5) in the His-Purkinje system and ventricular myocardium. This blockade slows Phase 0 of the cardiac action potential, leading to a decrease in conduction velocity and a characteristic widening of the QRS complex on ECG. QRS prolongation >100 ms is a marker of severe toxicity and predicts seizures and ventricular arrhythmias. While TCAs also block potassium channels (A), leading to QT prolongation, the QRS widening is specifically due to sodium channel blockade. Blockade of L-type calcium channels (C) is not a primary mechanism of TCA cardiotoxicity. Blockade of muscarinic receptors (D) contributes to anticholinergic effects like sinus tachycardia but not to QRS widening.
- A 30-year-old male with major depressive disorder reports that he stopped his previous antidepressant, sertraline, due to intolerable sexual dysfunction. He is seeking a new medication with a significantly lower likelihood of this adverse effect. Which of the following would be the most appropriate choice based on mechanism of action?
Answer: Bupropion
When treating depression with concerns about sexual side effects, you need to understand how different antidepressant mechanisms affect sexual function. Sexual dysfunction is primarily caused by increased serotonin activity, which inhibits sexual desire and performance through complex neurochemical pathways.
Bupropion (D) is the correct choice because it works through a completely different mechanism than serotonergic antidepressants. It's a norepinephrine-dopamine reuptake inhibitor that actually enhances dopaminergic activity in reward pathways, which can improve rather than impair sexual function. Bupropion has the lowest incidence of sexual side effects among all antidepressants and is often used specifically when sexual dysfunction is a concern.
The other options all significantly increase serotonin activity, making them poor choices for this patient. Paroxetine (A) is an SSRI like sertraline and actually has the highest rate of sexual dysfunction among SSRIs due to its potent serotonin reuptake inhibition and anticholinergic effects. Escitalopram (C) is also an SSRI with similar sexual side effect profiles to sertraline. Venlafaxine (B), while technically an SNRI (serotonin-norepinephrine reuptake inhibitor), primarily affects serotonin at therapeutic doses and carries significant risk of sexual dysfunction.
Remember this pattern: when sexual side effects are the primary concern with antidepressants, think mechanism of action. Serotonin enhancement = sexual problems, while dopamine/norepinephrine activity (bupropion) = preserved or enhanced sexual function. This makes bupropion unique among first-line antidepressants.
- Both venlafaxine (an SNRI) and amitriptyline (a TCA) inhibit the reuptake of serotonin and norepinephrine. Compared to amitriptyline, venlafaxine is considered to have a more favorable side-effect profile primarily because it lacks significant antagonist activity at which combination of receptors?
Answer: Muscarinic acetylcholine, histamine H1, and alpha-1 adrenergic receptors
When comparing antidepressants with similar mechanisms of action, the key difference often lies in their receptor binding profiles beyond their primary targets. Both venlafaxine and amitriptyline block serotonin and norepinephrine reuptake, but their side effect profiles differ dramatically due to additional receptor interactions.
Venlafaxine's superior tolerability stems from its selective action—it primarily blocks monoamine transporters without significant antagonism at other receptor systems. In contrast, tricyclic antidepressants like amitriptyline are notoriously "dirty drugs" that block multiple receptors beyond their intended targets.
The correct answer is D because amitriptyline's problematic side effects arise from its antagonism at muscarinic acetylcholine receptors (causing dry mouth, constipation, urinary retention, and cognitive impairment), histamine H1 receptors (causing sedation and weight gain), and alpha-1 adrenergic receptors (causing orthostatic hypotension and dizziness). Venlafaxine lacks significant activity at these receptors, explaining its cleaner side effect profile.
Option A is incorrect because neither drug significantly affects dopamine D2 or 5-HT2A receptors—these are more relevant to antipsychotics. Option B is wrong since 5-HT1A and beta-1 adrenergic receptors aren't primary contributors to the side effect differences between these medications. Option C references glutamate receptors, which aren't significantly involved in either drug's mechanism or side effect profile.
Remember this pattern: when comparing drugs with similar primary mechanisms, look for differences in "off-target" receptor binding to explain varying side effect profiles. TCAs are classic examples of drugs with extensive off-target effects.
- A patient is being switched from phenelzine to fluoxetine due to inadequate response. To minimize the risk of serotonin syndrome, what is the most appropriate clinical action regarding the timing of this medication change?
Answer: Stop phenelzine and wait at least 2 weeks before starting fluoxetine.
Combining an MAOI with an SSRI can cause life-threatening serotonin syndrome. Phenelzine is an irreversible inhibitor of monoamine oxidase. After discontinuing the drug, it takes approximately two weeks for the body to synthesize new MAO enzyme to restore normal function. Therefore, a minimum 14-day (2-week) washout period is mandatory after stopping an irreversible MAOI before an SSRI can be initiated. Options A and B are extremely dangerous and would precipitate a severe interaction. Option D (5 weeks) is the recommended washout period when switching from the long-acting SSRI fluoxetine to an MAOI, due to the long half-life of fluoxetine's active metabolite, norfluoxetine. This is a common point of confusion tested here.
- A 22-year-old college student with a history of bulimia nervosa presents with symptoms of major depressive disorder. Which of the following antidepressants is absolutely contraindicated in this patient due to an increased risk of seizures?
Answer: Bupropion
When you encounter questions about antidepressant selection in patients with eating disorders, you need to consider each medication's unique side effect profile and contraindications, particularly seizure risk.
Bupropion (D) is absolutely contraindicated in patients with bulimia nervosa due to a significantly increased seizure risk. This occurs because bulimia patients often have electrolyte imbalances (especially hypokalemia and hyponatremia) from purging behaviors, dehydration, and metabolic disturbances that lower the seizure threshold. Bupropion already carries an inherent seizure risk of approximately 0.4%, but this risk becomes unacceptably high in eating disorder patients. The FDA specifically lists eating disorders as an absolute contraindication for bupropion.
The other options are much safer choices in this population. Sertraline (A), an SSRI, has minimal seizure risk and is often first-line for depression with comorbid eating disorders. Duloxetine (B), an SNRI, also has low seizure potential and can be used safely in bulimia patients. Nortriptyline (C), while a tricyclic antidepressant with some seizure risk, doesn't carry the absolute contraindication that bupropion does in eating disorders.
Study tip: Remember the mnemonic "Bulimia Blocks Bupropion" for this absolute contraindication. On pharmacology exams, always consider patient-specific factors like eating disorders, seizure history, or electrolyte disturbances when selecting antidepressants. Bupropion questions often test knowledge of its contraindications: eating disorders, seizure disorders, and MAOIs.
- The FDA has issued a warning regarding dose-dependent QT interval prolongation with citalopram, recommending a maximum dose of 40 mg/day for most adults. This cardiotoxic effect is a result of the drug's inhibitory action on which of the following ion channels?
Answer: hERG/IKr potassium channels
Drug-induced QT prolongation is most commonly caused by blockade of the rapid component of the delayed rectifier potassium current (IKr). This current is conducted by channels encoded by the human ether-a-go-go-related gene (hERG). Blockade of these channels slows ventricular repolarization (Phase 3 of the cardiac action potential), which manifests as a prolonged QT interval on the ECG and increases the risk of torsades de pointes. Citalopram and its S-enantiomer, escitalopram, are known inhibitors of the hERG channel. Blockade of fast sodium channels (B) causes QRS widening, characteristic of TCAs. T-type calcium channels (C) and ryanodine receptors (D) are not the primary targets for this effect.
- A patient taking sertraline and tramadol presents with agitation, confusion, diaphoresis, tachycardia, and prominent myoclonus with hyperreflexia in the lower extremities. Which of the following findings would most specifically support a diagnosis of serotonin syndrome over neuroleptic malignant syndrome (NMS)?
Answer: Spontaneous or inducible clonus
Both serotonin syndrome (SS) and neuroleptic malignant syndrome (NMS) can present with altered mental status, autonomic instability (tachycardia, diaphoresis), and hyperthermia (B). Rhabdomyolysis can cause elevated CK in both (A). The key distinguishing feature is the nature of the neuromuscular findings. SS is a syndrome of neuromuscular hyperactivity, characterized by tremor, hyperreflexia, and myoclonus; clonus (spontaneous or inducible) is particularly characteristic. NMS, caused by dopamine D2 receptor blockade, is characterized by profound, generalized 'lead-pipe' rigidity (C) and bradyreflexia or hyporeflexia. Therefore, the presence of clonus is highly specific for serotonin syndrome.
- A patient stabilized on phenelzine for atypical depression attends a party and consumes aged cheese and red wine. They develop a severe headache, palpitations, and their blood pressure is measured at 210/120 mmHg. This hypertensive crisis is a direct result of phenelzine preventing the metabolism of which endogenous substance that is displaced from sympathetic nerve terminals by tyramine?
Answer: Norepinephrine
Phenelzine is an irreversible monoamine oxidase inhibitor (MAOI). Tyramine, found in aged foods, is an indirect-acting sympathomimetic. Normally, MAO-A in the gut and liver metabolizes ingested tyramine. When MAO-A is inhibited, tyramine enters the systemic circulation and is taken up into sympathetic nerve terminals, where it displaces large quantities of stored norepinephrine into the synapse. This massive release of norepinephrine acts on adrenergic receptors in the vasculature, causing severe vasoconstriction and hypertensive crisis. While MAOIs also increase serotonin (A) and dopamine (B), the acute peripheral hypertensive response is overwhelmingly driven by norepinephrine release. Acetylcholine (D) is not a monoamine and is not involved in this interaction.
- A patient with major depressive disorder and comorbid fibromyalgia is switched from escitalopram to duloxetine. While their mood and pain improve, they report a consistent increase in their resting blood pressure. This adverse effect is most directly attributable to duloxetine's inhibition of the:
Answer: Norepinephrine reuptake transporter (NET)
Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI). Its therapeutic effects in both depression and neuropathic pain are mediated by increasing synaptic concentrations of both serotonin and norepinephrine. The increase in blood pressure and heart rate is a well-known adverse effect of SNRIs and is directly related to the inhibition of the norepinephrine reuptake transporter (NET). Increased synaptic norepinephrine leads to greater stimulation of postsynaptic alpha-1 and beta-1 adrenergic receptors in the cardiovascular system, causing vasoconstriction and increased cardiac output. SERT inhibition (A) is not associated with hypertension. Duloxetine has negligible affinity for DAT (C). Blockade of alpha-1 receptors (D), a property of TCAs, would cause orthostatic hypotension, not hypertension.
- A patient who has been taking an SSRI for major depressive disorder for one year abruptly stops their medication. Within 48 hours, they experience dizziness, nausea, paresthesias ('electric shock' sensations), and anxiety. This presentation is most likely to occur with which SSRI?
Answer: Paroxetine
SSRI discontinuation syndrome is characterized by flu-like symptoms, insomnia, nausea, imbalance, sensory disturbances, and hyperarousal. The risk, onset, and severity are inversely related to the drug's half-life. Paroxetine has the shortest half-life (≈21 hours) among the listed options and lacks active metabolites, leading to a rapid fall in plasma levels and a higher incidence of a severe, rapid-onset discontinuation syndrome. Fluoxetine (A) has a very long half-life (4-6 days) and its active metabolite, norfluoxetine, has an even longer half-life (4-16 days), making it 'self-tapering' and associated with the lowest risk of discontinuation syndrome. Sertraline (B) and citalopram (D) have intermediate half-lives (≈26 and ≈35 hours, respectively) and are associated with a lower risk than paroxetine.
- A patient with major depression and significant insomnia fails to respond to sertraline. They are switched to mirtazapine. Unlike sertraline, mirtazapine enhances serotonergic and noradrenergic neurotransmission primarily through which mechanism?
Answer: Antagonism of presynaptic alpha-2 autoreceptors and heteroreceptors
Mirtazapine has a unique mechanism of action among antidepressants. It is a tetracyclic antidepressant that acts as a potent antagonist of central presynaptic alpha-2 adrenergic autoreceptors (on noradrenergic neurons) and heteroreceptors (on serotonergic neurons). These receptors normally function as a negative feedback mechanism, inhibiting the release of norepinephrine and serotonin, respectively. By blocking these receptors, mirtazapine 'cuts the brakes,' leading to increased release of both neurotransmitters. It is not an MAOI (A) or a significant reuptake inhibitor (B). While some antidepressants have 5-HT1A activity (D), it is not mirtazapine's primary mechanism for increasing NE and 5-HT levels.
- A patient with treatment-resistant depression is currently taking sertraline (an SSRI). A psychiatrist considers augmenting this with another agent. Which of the following agents, when added to sertraline, would most likely enhance antidepressant efficacy by acting on a different monoamine system with a lower risk of serotonin syndrome compared to other combinations?
Answer: Bupropion
The principle of augmentation is to add an agent with a complementary mechanism of action. Sertraline is an SSRI. Adding bupropion, a norepinephrine-dopamine reuptake inhibitor (NDRI), targets two different neurotransmitter systems (DA and NE) and is a common and effective augmentation strategy. Because bupropion has minimal effects on serotonin, the risk of serotonin syndrome is low. Adding another SSRI like fluvoxamine (A) is irrational. Adding an SNRI like duloxetine (B) adds noradrenergic activity but also significantly increases serotonergic load and the risk of serotonin syndrome. Adding an MAOI like phenelzine (D) is absolutely contraindicated due to the high risk of life-threatening serotonin syndrome.
- Venlafaxine exhibits a dose-dependent effect on neurotransmitter reuptake. At lower therapeutic doses (e.g., 75 mg/day), its pharmacological action most closely resembles that of which other agent?
Answer: Fluoxetine
Venlafaxine is an SNRI, but its affinity for the serotonin transporter (SERT) is approximately 30-fold higher than its affinity for the norepinephrine transporter (NET). Consequently, at lower doses (typically below 150 mg/day), it functions primarily as a selective serotonin reuptake inhibitor, with a mechanism and side effect profile similar to SSRIs like fluoxetine. The norepinephrine reuptake inhibition becomes clinically significant only at higher doses. Amitriptyline (B), a TCA, inhibits both SERT and NET from the start and has many other receptor actions. Selegiline (C) is an MAOI, and bupropion (D) is an NDRI, both with distinct mechanisms.
- A patient presents with major depressive disorder, severe initial insomnia, and chronic neuropathic pain. Which of the following antidepressants possesses a pharmacologic profile that would be most suitable for addressing all three conditions simultaneously?
Answer: Doxepin
This clinical scenario requires a drug that is an effective antidepressant, is sedating, and has analgesic properties for neuropathic pain. Doxepin, a tricyclic antidepressant (TCA), fits this profile perfectly. TCAs are effective antidepressants and are also first-line agents for many neuropathic pain conditions. Doxepin is one of the most potent H1 receptor antagonists among the TCAs, making it highly sedating and effective for insomnia. Fluoxetine (A) and bupropion (B) can be activating and may worsen insomnia; bupropion also lacks proven efficacy for neuropathic pain. Tranylcypromine (D), an MAOI, is not a first-line choice and is not typically used for its sedative or analgesic properties.
- A patient presents to the emergency department with a suspected antidepressant overdose. The patient is comatose, hypotensive, has dilated pupils, and an ECG shows sinus tachycardia with a QRS complex of 150 ms. An overdose of which agent is most consistent with this clinical picture?
Answer: Imipramine
This presentation is the classic toxidrome for a tricyclic antidepressant (TCA) overdose. Imipramine is a TCA. The key features are: coma (CNS depression), hypotension (alpha-1 adrenergic blockade), dilated pupils and tachycardia (anticholinergic effects), and a widened QRS complex (sodium channel blockade). Citalopram (A), an SSRI, is more likely to cause QT prolongation and seizures. Phenelzine (C), an MAOI, typically causes a hyperadrenergic state (hypertension, agitation) initially. Venlafaxine (D), an SNRI, can cause seizures and tachycardia, but profound QRS widening is much more characteristic of TCAs.
- The transdermal formulation of selegiline is approved for major depressive disorder, while the oral form is primarily used for Parkinson's disease. How does the transdermal route alter the key risk profile of selegiline when used for depression compared to its low-dose oral use for Parkinson's?
Answer: It bypasses first-pass metabolism, leading to non-selective MAO-A and MAO-B inhibition at therapeutic doses.
At low oral doses for Parkinson's, selegiline is selective for MAO-B due to extensive first-pass metabolism in the gut and liver, where MAO-A is abundant. The transdermal patch bypasses this first-pass metabolism, resulting in higher systemic concentrations of the parent drug. At these higher concentrations required for an antidepressant effect, selegiline loses its selectivity and inhibits both MAO-A and MAO-B throughout the body, including in the gut. Therefore, patients using the selegiline patch for depression must follow tyramine-restricted diets to prevent hypertensive crisis, just as with non-selective oral MAOIs.
